Alzamend Neuro Inc

NAS:ALZN (USA)   Ordinary Shares
$ 1.26 -0.02 (-1.56%) 11:08 PM EST
At Loss
Volume:
119.57K
Avg Vol (2M):
225.42K
Trade In:
Volume:
119.57K
At Loss
Avg Vol (2M):
225.42K

Business Description

Alzamend Neuro Inc
NAICS : 541714 SIC : 2833
ISIN : US02262M4078

Share Class Description:

ALZN: Ordinary Shares
Description
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.
Name Current Vs Industry Vs History
Cash-To-Debt 3.97
Equity-to-Asset -0.73
Debt-to-Equity -0.25
Debt-to-EBITDA -0.04
Piotroski F-Score 2/9
0
1
2
3
4
5
6
7
8
9
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 19.78
9-Day RSI 25.63
14-Day RSI 30.32
6-1 Month Momentum % -73.17
12-1 Month Momentum % -83.9

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 0.49
Quick Ratio 0.49
Cash Ratio 0.41

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -6.7
Name Current Vs Industry Vs History
ROA % -552.04
ROIC % -2757.67
ROC (Joel Greenblatt) % -3562.32

GF Value Rank

Name Current Vs Industry Vs History
EV-to-EBIT -0.77
EV-to-Forward-EBIT -1.58
EV-to-EBITDA -0.78
EV-to-Forward-EBITDA -0.65
EV-to-FCF -0.93
Earnings Yield (Greenblatt) % -129.87
FCF Yield % -108.07

Financials (Next Earnings Date:2024-12-13 Est.)

ALZN's 30-Y Financials
Income Statement Breakdown FY
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with NAS:ALZN

No Available Data

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

Alzamend Neuro Inc Executives

Details

GF Value

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $)
EPS (TTM) ($) -10.688
Beta 0.29
Volatility % 54.07
14-Day RSI 30.32
14-Day ATR ($) 0.107884
20-Day SMA ($) 1.43875
12-1 Month Momentum % -83.9
52-Week Range ($) 1.25 - 15.06
Shares Outstanding (Mil) 4.48

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 2
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Alzamend Neuro Inc Filings

Filing Date Document Date Form
No Filing Data

Alzamend Neuro Inc Stock Events

Financials Calendars
Event Date Price($)
No Event Data

Alzamend Neuro Inc Frequently Asked Questions

What is Alzamend Neuro Inc(ALZN)'s stock price today?
The current price of ALZN is $1.26. The 52 week high of ALZN is $15.06 and 52 week low is $1.25.
When is next earnings date of Alzamend Neuro Inc(ALZN)?
The next earnings date of Alzamend Neuro Inc(ALZN) is 2024-12-13 Est..
Does Alzamend Neuro Inc(ALZN) pay dividends? If so, how much?
Alzamend Neuro Inc(ALZN) does not pay dividend.

Press Release

Subject Date
No Press Release

Headlines

See More
  • 1
No news.
  • 1